June 27, 2024 02:47 PM EDT

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Nicole DeFeudis

Editor

The Supreme Court ruled against Purdue Pharma’s bankruptcy plan on Thursday, denying protection for the Sackler family from a “broad sweep of present and future …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Nicole DeFeudis

Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Immunology biotech Alumis secures $250M in shrunken IPO

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Immunology biotech Alumis secures $250M in shrunken IPO

With a $372M megaround, Formation Bio looks to in-license 10+ drugs